Travere Therapeutics, Inc. (TVTX) is a biopharmaceutical organization dedicated to determining, developing and commercializing therapies to enhance the lives of individuals suffering from rare, severe diseases. The company is based in San Diego, California, and was formerly known as Retrophin, Inc. It changed its name to Travere Therapeutics, Inc. in November 2020. The company was founded in 2010 and is listed on NASDAQ under the symbol "TVTX".
Travere Therapeutics specializes in identifying and bringing to market novel therapeutics that target the body's cellular metabolism. Their primary focus is conducting innovative research to discover treatments for rare diseases that currently have no effective therapy. The company's lead product candidate, sparsentan, is a potential therapeutic for the treatment of focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN).
The company has multiple clinical drug candidates and a rich product portfolio that cover a range of ailments including kidney disease, liver disease, and neurological disorders. Travere Therapeutics' robust research and development capabilities, coupled with a strategic use of partnerships and acquisitions, enable a steady pipeline of potential new therapies.
Apart from the pharmaceutical development process, Travere is also keen on patient advocacy, supporting and participating in initiatives that aim to improve the lives of those affected by rare diseases. The company believes that collaboration with patient communities is integral to understanding the unique challenges they face and to creating innovative solutions that address their needs.
Travere is known for its strong corporate governance that values transparency, integrity, and accountability. The company adheres to rigorous operational and ethical standards to ensure it can effectively deliver on its mission and create value for its shareholders.
In recent years, the company has been recognized in the biopharma industry for its leadership in rare disease research, dedication to patient advocacy, and commitment to corporate responsibility. Despite inevitable challenges and competition in the biopharmaceutical industry, Travere continues to strive unfazed, working towards their mission of transforming the lives of patients with unmet medical needs.
Travere Therapeutics, therefore, operates at the intersection of scientific innovation, medical advancement, and patient care, bridging the gap between the laboratory and the patient's bedside, and striving to bring hope and health to the rare disease community.